PCSK9

George Church, PhD: Rewriting Genomes to Eradicate Disease and Aging

FoundMyFitness

A gene target in base editing trials for hypercholesterolemia. Humans with natural null mutations for PCSK9 are healthy, indicating its safety and effectiveness as a therapeutic target.

AMA #3: supplements, women’s health, patient care, and more (EP.26) | The Peter Attia Drive

Peter Attia MD

Proprotein convertase subtilisin/kexin type 9, an enzyme that degrades LDL receptors; berberine is a weak inhibitor of this enzyme.

The impact of body fat on metabolic health | Peter Attia & Ethan Weiss

Peter Attia MD

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

Peter Attia MD

Proprotein convertase subtilisin kexin type 9, discovered in 2003, acts as a regulator of the LDL receptor, preventing its recycling and leading to higher LDL levels.

#19 – Dave Feldman: stress testing the lipid energy model

Peter Attia MD

A protein that regulates LDL receptor degradation. Hyper-functioning PCSK9 leads to fewer LDL receptors and higher LDL levels, while hypo-functioning PCSK9 leads to more LDL receptors and lower LDL levels.